PDF(Pubmed)
Abstract：
The \"2022 ACC/AHA Guideline for the Diagnosis and Management of Aortic Disease\" provides recommendations to guide clinicians in the diagnosis, genetic evaluation and family screening, medical therapy, endovascular and surgical treatment, and long-term surveillance of patients with aortic disease across its multiple clinical presentation subsets (ie, asymptomatic, stable symptomatic, and acute aortic syndromes).
A comprehensive literature search was conducted from January 2021 to April 2021, encompassing studies, reviews, and other evidence conducted on human subjects that were published in English from PubMed, EMBASE, the Cochrane Library, CINHL Complete, and other selected databases relevant to this guideline. Additional relevant studies, published through June 2022 during the guideline writing process, were also considered by the writing committee, where appropriate.
Recommendations from previously published AHA/ACC guidelines on thoracic aortic disease, peripheral artery disease, and bicuspid aortic valve disease have been updated with new evidence to guide clinicians. In addition, new recommendations addressing comprehensive care for patients with aortic disease have been developed. There is added emphasis on the role of shared decision making, especially in the management of patients with aortic disease both before and during pregnancy. The is also an increased emphasis on the importance of institutional interventional volume and multidisciplinary aortic team expertise in the care of patients with aortic disease.
A comprehensive literature search was conducted from January 2021 to April 2021, encompassing studies, reviews, and other evidence conducted on human subjects that were published in English from PubMed, EMBASE, the Cochrane Library, CINHL Complete, and other selected databases relevant to this guideline. Additional relevant studies, published through June 2022 during the guideline writing process, were also considered by the writing committee, where appropriate.
Recommendations from previously published AHA/ACC guidelines on thoracic aortic disease, peripheral artery disease, and bicuspid aortic valve disease have been updated with new evidence to guide clinicians. In addition, new recommendations addressing comprehensive care for patients with aortic disease have been developed. There is added emphasis on the role of shared decision making, especially in the management of patients with aortic disease both before and during pregnancy. The is also an increased emphasis on the importance of institutional interventional volume and multidisciplinary aortic team expertise in the care of patients with aortic disease.
摘要：
目的：“2022年ACC/AHA主动脉疾病诊断和管理指南”为指导临床医生的诊断提供了建议，遗传评估和家庭筛查，医学治疗,血管内和外科治疗，以及对主动脉疾病患者的多个临床表现子集的长期监测(即，无症状，症状稳定，和急性主动脉综合征）。
方法：从2021年1月至2021年4月进行了全面的文献检索，包括研究，reviews,以及PubMed以英文发表的关于人类受试者的其他证据，EMBASE,Cochrane图书馆,CINHL完成，以及与本指南相关的其他选定数据库。其他相关研究，在指南编写过程中，发布到2022年6月，写作委员会也审议了，在适当的地方。
■先前发布的AHA/ACC关于胸主动脉疾病指南的建议，外周动脉疾病,和二叶主动脉瓣疾病已经更新了新的证据来指导临床医生。此外,针对主动脉疾病患者的综合护理提出了新的建议.强调了共同决策的作用，特别是在妊娠前和妊娠期间主动脉疾病患者的管理中。这也越来越强调机构介入量和多学科主动脉团队专业知识在主动脉疾病患者护理中的重要性。
方法：从2021年1月至2021年4月进行了全面的文献检索，包括研究，reviews,以及PubMed以英文发表的关于人类受试者的其他证据，EMBASE,Cochrane图书馆,CINHL完成，以及与本指南相关的其他选定数据库。其他相关研究，在指南编写过程中，发布到2022年6月，写作委员会也审议了，在适当的地方。
■先前发布的AHA/ACC关于胸主动脉疾病指南的建议，外周动脉疾病,和二叶主动脉瓣疾病已经更新了新的证据来指导临床医生。此外,针对主动脉疾病患者的综合护理提出了新的建议.强调了共同决策的作用，特别是在妊娠前和妊娠期间主动脉疾病患者的管理中。这也越来越强调机构介入量和多学科主动脉团队专业知识在主动脉疾病患者护理中的重要性。
